ClinicalTrials.gg
CompletedNCT04880850ONWARDS 4Updated Dec 4, 2025Results posted

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)

A Phase 3 interventional study of Insulin icodec and Insulin glargine in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 116 sites in 9 countries. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
582
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
6th of 27
582 · median 84
Started
2021
with 4 others
Phase 3
9 of 27
none open now
Registered
18th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is one of 5 that started in 2021, is one of 9 in phase 3, and was the 18th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.

The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily.

Participants will either get insulin icodec that participants will have to inject once a week on the same day of the week or insulin glargine that participants will have to inject once a day at the same time every day. Which treatment participants will get is decided by chance. Participants will also get a mealtime insulin.The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach.

The study will last for about 8 months. participants will have 17 clinic visits and 13 phone calls with the study doctor.At 8 clinic visits participants will have blood samples taken. At 4 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 3 periods for a total of 13 weeks (about 3 months) during the study.

Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged above or equal to 18 years at the time of signing .
  • Diagnosed with type 2 diabetes mellitus (T2D) greater than or equal to 180 days prior to the day of screening.
  • (HbA1c) from 7.0-10.0% (53.0 85.8 mmol/mol) both inclusive at screening confirmed by central laboratory analysis.
  • Treated with once daily basal insulin (neutral protamine hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL) and 2-4 daily injections of bolus insulin analog (insulin aspart, faster acting insulin aspart, insulin lispro, insulin glulisine) greater than or equal to 90 days prior to the day of screening with or without any of the following anti-diabetic drugs/regimens with stable doses greater than or equal to 90 days prior to screening:

Metformin / Sulfonylureas / Meglitinides (glinides) / DPP-4 inhibitors / SGLT2 inhibitors / Thiazolidinediones / Alpha-glucosidase inhibitors / Oral combination products (for the allowed individual oral anti-diabetic drugs) / Oral or injectable GLP-1-receptor agonists

  • (BMI) below or equal to 40.0 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Any episodes (as declared by the subject or in the medical records.) of diabetic ketoacidosis within 90 days prior to the day of screening.
  • Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or within 180 days prior to the day of screening.
  • Chronic heart failure classified as being in Class IV at screening.
  • Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or ).
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
582 participants (actual)

Study arms

  • Experimental
    insulin icodec + insulin aspart

    Participants will get once weekly injections in combination with 2-4 times daily injections of insulin aspart

    Drug: Insulin icodec · Drug: Insulin aspart

  • Active comparator
    Insulin glargine + insulin aspart

    Participants will get once daily injections in combination with 2-4 times daily injections of insulin aspart

    Drug: Insulin glargine · Drug: Insulin aspart

Interventions

  • Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks

  • Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 26 weeks

  • Participants will receive subcutaneous (s.c.) injections of insulin aspart 2-4 times daily for 26 weeks

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c)

    Change in HbA1c from baseline (week 0) to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: Baseline (week 0), Week 26

Secondary outcomes

  1. Change in Fasting Plasma Glucose (FPG)

    Change in FPG from baseline (week 0) to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: Baseline (week 0), Week 26

  2. Percentage of Time in Target-range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System

    Percentage of time in target-range 3.9-10.0 mmol/L (70-180 milligrams per deciliter \[mg/dL\]) using continuous glucose monitoring (CGM) system from week 22 to week 26 is presented. Time in target range is defined as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: From week 22 to week 26

  3. Number of Severe Hypoglycaemic Episodes (Level 3)

    Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the on-treatment observation period. The on-treatment observation period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit, the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period.

    Time frame: From baseline (week 0) to week 31

  4. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL) Confirmed by Blood Glucose (BG) Meter)

    Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). The outcome data was evaluated based on the on-treatment observation period. The on-treatment observation period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit, the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period.

    Time frame: From baseline (week 0) to week 31

  5. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

    Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the in-trial observation period. The on-treatment observation period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit, the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period.

    Time frame: From baseline (week 0) to week 31

  6. Percentage of Time Spent Below 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System

    Percentage of time spent less than (\<) 3.0 mmol/L (54 mg/dL) using CGM system from week 22 to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: From week 22 to week 26

  7. Percentage of Time Spent Above 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System

    Percentage of time spent \> 10 mmol/L (180 mg/dL) using CGM system from week 22 to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: From week 22 to week 26

  8. Mean Weekly Insulin Dose

    Estimated mean weekly insulin dose during the last 2 weeks of treatment (from week 24 to week 26) is presented. The outcome data was evaluated based on the on-treatment observation period. The on-treatment observation period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit, the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period.

    Time frame: From week 24 to week 26

  9. Change in Body Weight

    Change in body weight from baseline (week 0) to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: Baseline (week 0), Week 26

07

Results

Posted Jul 2, 2025

Participant flow

The trial was conducted at 83 sites in 9 countries as follows: Belgium (5), India (9), Italy (6), Japan (9), Mexico (3), Netherlands (5), Romania (6), Russia (10), United States (30).

Participant flow — Overall Study
MilestoneInsulin IcodecInsulin Glargine
Started291291
Full analysis set (fas)291291
Safety analysis set (sas)291291
Completed275273
Not completed1618
Withdrew: Death21
Withdrew: Lost to follow-up36
Withdrew: Physician decision21
Withdrew: Withdrawal by subject910

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c)

Change in HbA1c from baseline (week 0) to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
Baseline (week 0), Week 26
Reported as:
Least squares mean · Percentage (%) of HbA1c
Change in Glycated Haemoglobin (HbA1c)
Percentage (%) of HbA1cInsulin IcodecInsulin Glargine
Change in Glycated Haemoglobin (HbA1c)-1.16 ± 0.05-1.18 ± 0.05
Statistical analysis
  • Insulin Icodec vs Insulin Glargine · ANCOVA · p = <0.0001 · Treatment difference: 0.02 · 95% CI -0.11 to 0.15
SecondaryChange in Fasting Plasma Glucose (FPG)

Change in FPG from baseline (week 0) to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
Baseline (week 0), Week 26
Reported as:
Least squares mean · Millimoles per liter (mmol/L)
Change in Fasting Plasma Glucose (FPG)
Millimoles per liter (mmol/L)Insulin IcodecInsulin Glargine
Change in Fasting Plasma Glucose (FPG)-1.75 ± 0.16-1.61 ± 0.16
SecondaryPercentage of Time in Target-range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System

Percentage of time in target-range 3.9-10.0 mmol/L (70-180 milligrams per deciliter \[mg/dL\]) using continuous glucose monitoring (CGM) system from week 22 to week 26 is presented. Time in target range is defined as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
From week 22 to week 26
Reported as:
Mean · Percentage (%) of time
Percentage of Time in Target-range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System
Percentage (%) of timeInsulin IcodecInsulin Glargine
Percentage of Time in Target-range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System66.88 ± 15.6266.44 ± 16.17
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3)

Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the on-treatment observation period. The on-treatment observation period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit, the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period.

Time frame:
From baseline (week 0) to week 31
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin IcodecInsulin Glargine
Number of Severe Hypoglycaemic Episodes (Level 3)73
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL) Confirmed by Blood Glucose (BG) Meter)

Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). The outcome data was evaluated based on the on-treatment observation period. The on-treatment observation period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit, the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period.

Time frame:
From baseline (week 0) to week 31
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL) Confirmed by Blood Glucose (BG) Meter)
EpisodesInsulin IcodecInsulin Glargine
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL) Confirmed by Blood Glucose (BG) Meter)937935
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the in-trial observation period. The on-treatment observation period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit, the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period.

Time frame:
From baseline (week 0) to week 31
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin IcodecInsulin Glargine
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)944938
SecondaryPercentage of Time Spent Below 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System

Percentage of time spent less than (\<) 3.0 mmol/L (54 mg/dL) using CGM system from week 22 to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
From week 22 to week 26
Reported as:
Mean · Percentage (%) of time
Percentage of Time Spent Below 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System
Percentage (%) of timeInsulin IcodecInsulin Glargine
Percentage of Time Spent Below 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System0.73 ± 1.140.61 ± 1.07
SecondaryPercentage of Time Spent Above 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System

Percentage of time spent \> 10 mmol/L (180 mg/dL) using CGM system from week 22 to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
From week 22 to week 26
Reported as:
Mean · Percentage (%) of time
Percentage of Time Spent Above 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System
Percentage (%) of timeInsulin IcodecInsulin Glargine
Percentage of Time Spent Above 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System30.47 ± 15.9031.30 ± 16.67
SecondaryMean Weekly Insulin Dose

Estimated mean weekly insulin dose during the last 2 weeks of treatment (from week 24 to week 26) is presented. The outcome data was evaluated based on the on-treatment observation period. The on-treatment observation period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit, the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period.

Time frame:
From week 24 to week 26
Reported as:
Least squares mean · Units of insulin
Mean Weekly Insulin Dose
Units of insulinInsulin IcodecInsulin Glargine
Mean Weekly Insulin Dose513.54 (486.10 to 542.52)559.05 (528.63 to 591.22)
SecondaryChange in Body Weight

Change in body weight from baseline (week 0) to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of the last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
Baseline (week 0), Week 26
Reported as:
Least squares mean · Kilograms (kg)
Change in Body Weight
Kilograms (kg)Insulin IcodecInsulin Glargine
Change in Body Weight2.73 ± 0.292.16 ± 0.40

Adverse events

Collected over From baseline (week 0) to week 31.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Icodec2/291 (0.7%)22/291 (7.6%)48/291 (16.5%)
Insulin Glargine1/291 (0.3%)25/291 (8.6%)44/291 (15.1%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventInsulin IcodecInsulin Glargine
COVID-19 pneumoniaInfections and infestations4/2911/291
HypoglycaemiaMetabolism and nutrition disorders3/2910/291
Cardiac failure congestiveCardiac disorders0/2912/291
Coronary artery diseaseCardiac disorders1/2912/291
Diabetic retinal oedemaEye disorders0/2912/291
Myocardial infarctionCardiac disorders2/2910/291
PneumoniaInfections and infestations2/2910/291
Acute kidney injuryRenal and urinary disorders1/2910/291
Acute myocardial infarctionCardiac disorders1/2911/291
Angina pectorisCardiac disorders1/2911/291
Most frequent other events
Most frequent other events
EventInsulin IcodecInsulin Glargine
COVID-19Infections and infestations25/29122/291
Diabetic retinopathyEye disorders12/29115/291
DiarrhoeaGastrointestinal disorders15/2919/291

Baseline characteristics

Full analysis set (FAS) included all randomised participants from baseline (week 0) to week 26.

Age, Continuous
Age, Continuous(Years)Insulin IcodecInsulin GlargineTotal
Mean59.67 ± 10.1359.91 ± 9.9259.79 ± 10.02
Sex: Female, Male
Sex: Female, Male(Participants)Insulin IcodecInsulin GlargineTotal
Female137141278
Male154150304
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin IcodecInsulin GlargineTotal
Hispanic or Latino5253105
Not Hispanic or Latino239237476
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin IcodecInsulin GlargineTotal
American Indian or Alaska Native011
Asian9593188
Native Hawaiian or Other Pacific Islander011
Black or African American13821
White183187370
More than one race000
Unknown or Not Reported011
08

Study locations

116 sites
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72204, United States
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • John Muir Physicians Network
    Concord, California 94520, United States
  • Valley Research
    Fresno, California 93720, United States
  • Diabetes/Lipid Mgmt & Res Ctr
    Huntington Beach, California 92648, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Clinical Trials Research_Sacramento_0
    Sacramento, California 95821, United States
  • Diabetes Research Center
    Tustin, California 92780, United States
  • Coastal Metabolic Research Center
    Ventura, California 93003, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Chase Medical Research LLC
    Waterbury, Connecticut 06708, United States
  • MedStar Diabetes Institute
    Washington D.C., District of Columbia 20010, United States
  • Jacksonville Ctr For Clin Res
    Jacksonville, Florida 32216, United States
  • Clinical Trial Res Assoc,Inc
    Plantation, Florida 33324, United States
  • Metabolic Research Institute Inc
    West Palm Beach, Florida 33401, United States
  • Atlanta VA Medical Center
    Decatur, Georgia 30033, United States
  • Physicians Research Assoc. LLC
    Lawrenceville, Georgia 30046, United States
  • East West Med Res Inst
    Honolulu, Hawaii 96814, United States
  • Saltzer Medical Group Research
    Nampa, Idaho 83686-6011, United States
  • Velocity Clin. Res Valparaiso
    Valparaiso, Indiana 46383, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • MassResearch, LLC
    Waltham, Massachusetts 02453, United States
  • Jefferson City Medical Group, PC
    Jefferson City, Missouri 65109, United States
  • VA NEB - Western IA Health Stm
    Omaha, Nebraska 68105, United States
  • Methodist Physicians Clin
    Omaha, Nebraska 68114, United States
  • Palm Research Center Inc-Vegas
    Las Vegas, Nevada 89148, United States
  • AMC Community Endocrinology
    Albany, New York 12206, United States
  • Northport VA Medical Center_Northport_0
    Northport, New York 11768, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Southgate Medical Group, LLP
    West Seneca, New York 14224, United States
  • Mountain Diabetes & Endocrine Center
    Asheville, North Carolina 28803, United States
  • Physician's East Endocrinology
    Greenville, North Carolina 27834, United States
  • Your Diabetes Endocrine Nutrition Group, Inc.
    Mentor, Ohio 44060, United States
  • Oregon Health & Science University_Portland_0
    Portland, Oregon 97239, United States
  • Indiana-Armstrong Endocrinology Associates
    Indiana, Pennsylvania 15701, United States
  • Prisma Health-Upstate
    Greenville, South Carolina 29605-4254, United States
  • AM Diabetes And Endocrinology Center
    Bartlett, Tennessee 38133, United States
  • WR-ClinSearch, LLC
    Chattanooga, Tennessee 37421, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Vanderbilt Diab Obes Clin Tri
    Nashville, Tennessee 37212, United States
  • Amarillo Med Spec LLP
    Amarillo, Texas 79106, United States
  • Texas Diab & Endo, P.A.
    Austin, Texas 78731, United States
  • Texas Diabetes & Endocrinology
    Austin, Texas 78749, United States
  • Osvaldo A. Brusco MD PA
    Corpus Christi, Texas 78414, United States
  • Baylr Sctt White Rs Inst, Endo
    Dallas, Texas 75226, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • UT Southwestern Med Cntr
    Dallas, Texas 75390-9302, United States
  • Protenium Clinical Research_Hurst
    Fort Worth, Texas 76113, United States
  • DCOL Ctr for Clin Res
    Longview, Texas 75605, United States
  • Capital Clin Res Ctr,LLC
    Olympia, Washington 98502, United States
  • Imeldaziekenhuis - Bonheiden - Department of Endocrinology
    Bonheiden, 2820, Belgium
  • CHU Helora - Site Warquignies
    Boussu, 7300, Belgium
  • Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie
    Brussels, 1200, Belgium
  • UZA - UZ Antwerpen - Department of Endocrinology
    Edegem, 2650, Belgium
  • UZ Leuven - Endocrinology
    Leuven, 3000, Belgium
  • Kurnool Medical Collage
    Kurnool, Andhra Pradesh 518002, India
  • Medanta - The Medicity Multi-Speciality Hospital, Gurugram
    Gurgaon, Haryana 122001, India
  • St.John's Hospital
    Bangalore, Karnataka 560034, India
  • Bangalore Clinisearch
    Bangalore, Karnataka 560043, India
  • Lifecare Hospital and Research Centre
    Bangalore, Karnataka 560092, India
  • Belgaum Diabetes Centre
    Belagavi, Karnataka 590001, India
  • Manipal Hospital, Hebbal, Bengaluru
    Bengaluru, Karnataka 560 024, India
  • Renai Medicity
    Kochi, Kerala 682025, India
  • Prince Aly Khan Hospital
    Mumbai, Maharashtra 400010, India
  • BSES MG hospital
    Mumbai, Maharashtra 400058, India
  • Grant Medical Foundation
    Pune, Maharashtra 411001, India
  • Max Super Speciality Hospital, Saket
    New Delhi, National Capital Territory of Delhi 110017, India
  • Fortis Hospital, Shalimar Bagh, New Delhi
    New Delhi, National Capital Territory of Delhi 110088, India
  • Maulana Azad Medical College
    Delhi, New Delhi 110002, India
  • All India Institute of Medical Sciences
    New Dehli, New Delhi 110029, India
  • S.C.B. Medical College
    Cuttack, Odisha 753007, India
  • Diabetes, Thyroid and Endocrine Centre
    Jaipur, Rajasthan 302006, India
  • A.O.U. Università Studi della Campania "Luigi Vanvitelli"
    Naples, Campania 80138, Italy
  • Azienda Ospedaliero-Universitaria Renato Dulbecco
    Catanzaro, Cz 88100, Italy
  • Istituto Scientifico San Raffaele
    Milan, MI 20132, Italy
  • A.O.Universitaria S.ORSOLA-MALPIGHI - U.O.Endocrinologia e Cura
    Bologna, 40138, Italy
  • Università degli Studi G. D'Annunzio
    Chieti, 66100, Italy
  • Universita Degli Studi Di Roma La Sapienza - Policlinico Umberto I Medicina Sperimentale
    Roma, 00161, Italy
  • Hayashi Diabetes Clinic_Internal Medicine and Diabetes Medicine
    Chigasaki-shi, Kanagawa, Japan 253-0044, Japan
  • Futata Tetsuhiro Clinic Meinohama_Internal medicine
    Fukuoka-shi, Fukuoka, 819-0006, Japan
  • Sasaki Internal Medicine
    Hokkaido, 062-0007, Japan
  • Naka Kinen Clinic_Internal medicine
    Ibaraki, 311-0113, Japan
  • Sugimoto Clinic,Internal Medicine
    Kitakyusyu-shi, Fukuoka, 800-0222, Japan
  • Shimizu Clinic Fusa
    Saitama, 336-0967, Japan
  • Oyama East Clinic_Internal Medicine
    Tochigi, 323-0022, Japan
  • The Jikei University Hospital Dept of Diabetes, Metabolic
    Tokyo, 105-8471, Japan
  • Noritake Clinic
    Ushiku-shi, Ibaraki, 300-1207, Japan
  • Centro de Investigacion Medica de Occidente S.C.
    Zapopan, Jalisco 45116, Mexico
  • Hospital Universitario Dr. José Eleuterio González_Monterrey
    Monterrey, Nuevo León 64460, Mexico
  • Unidad Biomedica Avanzada Monterrey
    Monterrey, Nuevo León 64460, Mexico
  • Gelre Ziekenhuizen Apeldoorn
    Apeldoorn, 7334 DZ, Netherlands
  • Rijnstate Ziekenhuis
    Arnhem, 6815 AD, Netherlands
  • Maxima Medisch Centrum
    Eindhoven, 5631 BM, Netherlands
  • Bethesda Diabetes Research Center en Bethesda ziekenhuis
    Hoogeveen, 7909 AA, Netherlands
  • Maastricht Universitair Medisch Centrum
    Maastricht, 6229 HX, Netherlands
  • Ikazia Ziekenhuis
    Rotterdam, 3083 AN, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
    Bucharest, Bucurestii 020475, Romania

Showing the first 100 of 116 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Philis-Tsimikas A, Bajaj HS, Begtrup K, Cailleteau R, Gowda A, Lingvay I, Mathieu C, Russell-Jones D, Rosenstock J. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes Obes Metab. 2023 Feb;25(2):331-341. doi: 10.1111/dom.14871. Epub 2022 Oct 14. PubMed 36106652 ↗
  • Mathieu C, Asbjornsdottir B, Bajaj HS, Lane W, Matos ALSA, Murthy S, Stachlewska K, Rosenstock J. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023 Jun 10;401(10392):1929-1940. doi: 10.1016/S0140-6736(23)00520-2. Epub 2023 May 5. PubMed 37156252 ↗
  • Mohan V, Kesavadev J, Murthy LS, Anil G, Chandrappa M, Kar S, Mishra S. Efficacy and Safety of Once-Weekly Insulin Icodec in Indian Participants with Diabetes: Results from ONWARDS 1, 4, and 6 Studies. Diabetes Ther. 2025 Nov;16(11):2193-2212. doi: 10.1007/s13300-025-01799-4. Epub 2025 Oct 6. PubMed 41051694 ↗
  • Philis-Tsimikas A, Krogsdahl Bache J, Fu A, Kellerer M, Salvesen-Sykes K, Bain SC. Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec. Diabetes Ther. 2025 Aug;16(8):1615-1631. doi: 10.1007/s13300-025-01745-4. Epub 2025 Jun 4. PubMed 40465144 ↗
  • Riddell MC, Heller S, Carstensen L, Rocha TMP, Kehlet Watt S, Woo VC. The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1-5. Diabetologia. 2025 Jul;68(7):1416-1422. doi: 10.1007/s00125-025-06414-6. Epub 2025 Apr 5. PubMed 40186685 ↗
  • Watada H, Asbjornsdottir B, Nishida T, Nishimura R, Yamamoto Y, Yamauchi T, Kadowaki T. Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials. Diabetes Obes Metab. 2024 Dec;26(12):5882-5895. doi: 10.1111/dom.15960. Epub 2024 Sep 30. PubMed 39344833 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jun 2022, 13 months.

Results were first posted in Jul 2025, 3 years after primary completion. A results delay was requested in Jun 2023.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2021
First posted
May 11, 2021
StartActual
May 14, 2021
Primary completionActual
Jun 16, 2022
CompletionActual
Jun 16, 2022
Results delay requested
Jun 15, 2023
Results first posted
Jul 2, 2025
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04880850
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 11, 2021
Start date
May 14, 2021
Primary completion
Jun 16, 2022
Completion
Jun 16, 2022
Results posted
Jul 2, 2025
Last update
Dec 4, 2025

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion